OncoMatch/Clinical Trials/NCT04661020
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
Is NCT04661020 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CD19 CAR-T cells for non-hodgkin lymphoma,b cell.
Treatment: CD19 CAR-T cells — A Study of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MYC rearrangement
HGBCL involving combined rearrangements of MYC, bcl-2 and bcl-6
Required: BCL2 rearrangement
HGBCL involving combined rearrangements of MYC, bcl-2 and bcl-6
Required: BCL6 rearrangement
HGBCL involving combined rearrangements of MYC, bcl-2 and bcl-6
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody — preconditioning
regimen consisting of CD20 monoclonal antibody，lenalidomide and Brutons tyrosine kinase inhibitor for two courses
Must have received: immunomodulatory agent (lenalidomide) — preconditioning
regimen consisting of CD20 monoclonal antibody，lenalidomide and Brutons tyrosine kinase inhibitor for two courses
Must have received: Brutons tyrosine kinase inhibitor — preconditioning
regimen consisting of CD20 monoclonal antibody，lenalidomide and Brutons tyrosine kinase inhibitor for two courses
Cannot have received: CAR-T cell therapy
Previously treated with any CAR-T cell product or other genetically modified T cell therapies
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify